G-Lomustin10mg
Type:Capsule
Generic Name:Lomustine
Manufacturer:Gonoshasthaya Pharmaceuticals Ltd.
Price:৳70.00
Indication
Brain tumours, Hodgkin's disease, Lung cancer, Malignant melanoma
Administration
Should be taken on an empty stomach. Take on an empty stomach. May be taken at bedtime to reduce occurrence of nausea.
Adult Dose
Oral Brain tumours; Hodgkin's disease, resistant or relapsed; Malignant melanoma; Lung cancer Adult: 100-130 mg/m2 as a single dose every 6 wk. Adjust dose according to platelet and leukocyte counts. Compromised marrow function: 100 mg/m2 as a single dose every 6 wk.
Child Dose
Oral Brain tumours; Hodgkin's disease, resistant or relapsed; Malignant melanoma; Lung cancer Child: 75-150 mg/m2 as a single dose every 6 wk. Readjust dose according to platelet and leukocyte counts.
Renal Dose
Renal impairment: CrCl (ml/min) Dosage Recommendation 10-50 Admin 75% of normal dose. <10 Admin 25-50% of normal dose.
Contraindication
Pregnancy and lactation.
Mode of Action
Lomustine inhibits the synthesis of DNA and RNA via alkylation although carbamoylation and modification of cellular proteins may also be involved.
Precaution
Monitor CBC with differential platelet count wkly for at least 6 wk after a dose. Periodically perform pulmonary function studies and LFTs. Lactation: Unknown if metabolites present in breast milk; avoid nursing during treatment and for 2 weeks after final dose
Side Effect
>10% Nausea (54%),Vomiting (54%) 1-10% Neurotoxicity,Myelosuppression (delayed 4-5 weeks) Frequency Not Defined Ataxia,Lethargy,Disorientation,Stomatitis,Mucositis,Pulmonary fibrosis (rare),Pulmonary toxicity,Elevated LFTs,Leukemia,Renal toxicity,Hepatic toxicity,Infertility,Alopecia,Optic atrophy (rare) Potentially Fatal: Delayed bone marrow suppression and permanent marrow damage following prolonged use.
Interaction
Increased levels/effects with CYP2D6 inhibitors.